Walgreens Agrees To Oversight, Settles Insulin Pen Overdispensing, Discount Pricing Claims
Executive Summary
DOJ settlements totaling $269m resolve two False Claims Act cases; company enters corporate integrity agreement requiring independent review organization to assess claims.
You may also be interested in...
AmerisourceBergen Settlement On Injectable Drug Repackaging Includes Forfeiture Of Exec Pay
Corporate integrity agreement attached to second DOJ settlement over repackaging of injectable cancer drugs would require recoupment of exec performance pay following misconduct.
Companies Reveal Hurdles In Providing Drugs Via Expanded Access Programs
GSK, Stealth BioTherapeutics and Blueprint Medicines discuss the difficulties getting participation of physicians, the excessive cost of expanded access, and whether physicians should report research data.
Current Pathways For Rare Disease Drugs Are Not Optimal, US FDA’s Califf Says
Anticipating a ‘tsunami of therapies’ for rare diseases, commissioner says the agency will have to think of creative approaches and employ regulatory flexibility for them. FDA considers copying the oncology center’s Project Facilitate for expanded access to other diseases.